Pilot trial of intravenous (IV) infusion of a replication selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 in treatment of refractory cancer patients

被引：0
|
作者：
Nemunaitis, J
Cunningham, C
Tong, A
Edelman, G
Paulson, S
Mitch, D
Post, L
Freeman, S
机构：
[1] US Oncol, Dallas, TX USA
[2] Onyx Corp, Richmond, CA USA
来源：
CANCER GENE THERAPY | 2003年 / 10卷
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
33
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 21 条
  • [21] Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial
    Buti, S.
    Lazzarelli, S.
    Simonelli, C.
    Venturini, S.
    Spazzapan, S.
    Lo Re, G.
    Mattioli, R.
    Chiesa, M. Dalla
    Brighenti, M.
    Passalacqua, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
123